Drug profile

The FDA adverse-event record for Tiletamine+Zolazepam

17 FDA reports name Tiletamine+Zolazepam, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#1988 of 2,679
by report volume (all drugs)
17
adverse-event reports
23.5%
death-coded share
Cat
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Tiletamine+Zolazepam ranks #1937 of 2679 by total reports (17). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1937
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Tiletamine+Zolazepam has 17 reports now versus 15 in that prior snapshot: 2 more (13.3%).

Report change
+2
Death-coded reports
+0
Death-coded share
−3.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Tiletamine+Zolazepam changes

Signature read: Tiletamine+Zolazepam's 23.5% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
4
Deaths Reported
23.5%
Death-coded share of reports

Active Ingredients

Tiletamine+Zolazepam

Administration Routes

UnknownParenteralIntravenousIntramuscularOther

Species Affected

Cat 16
Dog 1

Most Affected Breeds

Domestic Shorthair 9
Cat (unknown) 3
Crossbred Feline/cat 1
Poodle (unspecified) 1
Domestic Mediumhair 1
Siamese 1
Domestic Longhair 1

Most Reported Reactions

Hyperactivity 5
Dysphoria 5
Not eating 4
Death by euthanasia 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Death 2
Elevated temperature 2
Dilated pupils 2
Hypotension 2
Lack of efficacy - NOS 1
Recovery prolonged 1
Incorrect route of drug administration 1

Outcome Breakdown

Outcome Unknown
5 (29.4%)
Recovered/Normal
5 (29.4%)
Ongoing
3 (17.6%)
Euthanized
2 (11.8%)
Died
2 (11.8%)

Tiletamine+Zolazepam: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Tiletamine+Zolazepam (#1988 of 2,679 by report volume); death-coded 23.5%. PlainBreed drug row · death-coded share stamp 23.5% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →